Several other SMARCB1 mutant cancers, including malignant rhabdoid tumors (MRT) and atypical teratoid rhabdoid tumors (ATRT) are candidates for treatment with EZH2 inhibitors [89,90]. Here, EZH2 is linked to atypical teratoid rhabdoid tumor.